AI News Sentiment & Analysis
IDEAYA Biosciences, Inc. (IDYA) — AI News Sentiment & Analysis
3 recent AI analyses of IDEAYA Biosciences, Inc. (IDYA) stock news and press releases, with sentiment and confidence scoring updated continuously.
IDEAYA and Servier Dose First Patient in Global Phase 3 Registrational Trial for Uveal Melanoma Adjuvant Therapy
BullishClinical ResultsFirst patient dosed in the global Phase 3 OptimUM-11 registrational trial. (Timing: Trial is expected to enroll approximately 450 patients.)Sep 9, 2026IDEAYA Biosciences Initiates Phase 1/2 Clinical Study for IDE892 in MTAP-Deleted Pancreatic and Lung Cancers
BullishClinical ResultsEnrollment of the first patient in the Phase 1/2 clinical study for IDE892, a potential best-in-class PRMT5 inhibitor for MTAP-deleted pancreatic and lung cancers. This is a critical operational milestone for its pipeline. (Timing: Initial data or further trial progression updates in the next 12-24 months, with monotherapy expansion anticipated in Q3 2026.)Jun 15, 2026IDEAYA Biosciences Reports Positive Phase 2/3 Clinical Results and FDA Submission Plans, Reiterates Long Cash Runway
BullishClinical ResultsPositive Phase 2/3 OptimUM-02 clinical trial results for darovasertib, leading to planned NDA submission under FDA's Real-Time Oncology Review (RTOR) program. Further clinical data updates from other pipeline assets are also expected. (Timing: NDA filing in H2 2026; ASCO presentation and other clinical data updates in H2 2026.)May 5, 2026
Want the full picture?
These are AI analyses of recent press releases. Sign up to see full reasoning, confidence details, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is IDEAYA Biosciences, Inc. (IDYA) bullish or bearish right now?
AI Sentiment on IDYA: 3 Bullish.
What was the latest AI analysis for IDEAYA Biosciences, Inc. (IDYA)?
The latest analysis was published on 9/9/2026 with the headline: "IDEAYA and Servier Dose First Patient in Global Phase 3 Registrational Trial for Uveal Melanoma Adjuvant Therapy".
How does Bekodia analyze IDEAYA Biosciences, Inc. (IDYA) stock?
Bekodia uses advanced AI models to process IDEAYA Biosciences, Inc. (IDYA) press releases and news in real-time, extracting sentiment, confidence scores, and key catalysts while filtering out market noise.